ArticleInternational journal of women's health2026
Global Burden of Polycystic Ovary Syndrome: A Systematic Analysis of Pre- and Post-Pandemic Trends from the 2021 Global Burden of Disease Study (1990-2021).
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study systematically examines the long-term trends in the global burden of Polycystic ovary syndrome (PCOS) across 204 countries and territories, with a specific focus on comparing pre-pandemic (1990-2019) and post-pandemic (2019-2021) periods. Methods: Using data from the Global Burden of Disease (GBD) 2021 for women aged 15-54, we estimated incidence, prevalence, and years lived with disability (YLDs). Age-standardized rates (ASIR, ASPR, ASYR) and estimated annual percentage change (EAPC) were calculated. Joinpoint, Age-Period-Cohort, and Bayesian models were used to analyze trends from 1990-2021 and project burden to 2050. Mendelian randomization (MR) assessed whether anxiety and guilt contribute to PCOS risk. Results: All burden measures increased globally from 1990 to 2021. Post-2019, the rate of increase (EAPC) accelerated significantly compared to the pre-pandemic period. High-SDI regions showed the lowest pre-pandemic growth but the largest increases during the pandemic. Health inequalities modestly improved by 2021. Projections indicate continued growth, with ASIR, ASPR, and ASYR reaching 73.66, 2104.41, and 18.37 per 100,000 by 2050, respectively. MR supports anxiety and guilt as likely risk factors. Conclusion: The post-pandemic rise in PCOS burden underscores systemic vulnerabilities in women's endocrine healthcare during health emergencies and signals a growing global health challenge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.